These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 19448681)
41. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618 [TBL] [Abstract][Full Text] [Related]
42. HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer. Fleskens AJ; Lalisang RI; Bos GM; van Gelder M; Jansen RL; Schouten HC Bone Marrow Transplant; 2010 Mar; 45(3):464-7. PubMed ID: 19633692 [TBL] [Abstract][Full Text] [Related]
43. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Ueno NT; Cheng YC; Rondón G; Tannir NM; Gajewski JL; Couriel DR; Hosing C; de Lima MJ; Anderlini P; Khouri IF; Booser DJ; Hortobagyi GN; Pagliaro LC; Jonasch E; Giralt SA; Champlin RE Blood; 2003 Nov; 102(10):3829-36. PubMed ID: 12881308 [TBL] [Abstract][Full Text] [Related]
45. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI; Zimmerman T; Stadler WM; Gajewski TF; Vogelzang NJ J Clin Oncol; 2002 Apr; 20(8):2017-24. PubMed ID: 11956260 [TBL] [Abstract][Full Text] [Related]
46. Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. Busca A; Novarino A; de Fabritiis P; Picardi A; Zeuli M; Locatelli F; Bertetto O; Falda M Hematology; 2006 Jun; 11(3):171-7. PubMed ID: 17325957 [TBL] [Abstract][Full Text] [Related]
47. Successful nonmyeloablative allogeneic stem cell transplantation for therapy-related acute myelogenous leukemia in a patient with preexisting visceral fungal infection. Ostronoff F; Ostronoff M; Calixto R; Maior AP; Sucupira A; Florêncio R; Domingues M J Pediatr Hematol Oncol; 2011 Jan; 33(1):62-4. PubMed ID: 20463605 [TBL] [Abstract][Full Text] [Related]
48. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Carella AM; Beltrami G; Corsetti MT; Nati S; Musto P; Scalzulli P; Gonella R; Ballestrero A; Patrone F Lancet; 2005 Jul 23-29; 366(9482):318-20. PubMed ID: 16039336 [TBL] [Abstract][Full Text] [Related]
49. Is there a role for dose-intensive chemotherapy with stem cell rescue in breast cancer? Williams SF Oncology (Williston Park); 2002 Dec; 16(12):1643-6, 1649; discussion 1650, 1655-6. PubMed ID: 12520640 [TBL] [Abstract][Full Text] [Related]
50. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Bishop MR Clin Breast Cancer; 2003 Apr; 4(1):39-45. PubMed ID: 12744757 [TBL] [Abstract][Full Text] [Related]
58. Nonmyeloablative allogeneic stem cell transplantation for nasopharyngeal carcinoma. Chia WK; Wang WW; Lim WT; Tai WM; Sun L; Thng CH; Soe Y; Yap SP; Tan EH; Toh HC Oncologist; 2010; 15(11):1192-7. PubMed ID: 20980417 [TBL] [Abstract][Full Text] [Related]
59. Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Reece DE; Foon KA; Bhattarcharya-Chatterjee M; Adkins D; Broun ER; Connaghan DG; Dipersio JF; Holland HK; Howard DA; Hale GA; Klingemann HG; Munn RK; Raptis A; Phillips GL Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S152-7. PubMed ID: 12620153 [TBL] [Abstract][Full Text] [Related]